National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Polatuzumab vedotin (Polivy®) HTA ID: 19052

Polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT).

NCPE Assessment Process Complete
Rapid Review commissioned 03/12/2019
Rapid Review completed 27/01/2020
Rapid Review Outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of polatuzumab vedotin (Polivy®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 26/02/2020
Pre-submission consultation with Applicant 31/03/2020
Full submission received from Applicant 10/07/2020
Preliminary review sent to Applicant 27/10/2020
NCPE assessment re-commenced 25/11/2020
Factual accuracy check sent to Applicant 26/01/2021
NCPE assessment re-commenced 02/02/2021
NCPE assessment completed 16/02/2021
NCPE assessment outcome The NCPE recommends that polatuzumab vedotin (Polivy®) be considered for reimbursement if cost effectiveness can be improved relative to existing treatments.*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.